Leerink Partnrs Has Negative Outlook of TNDM FY2028 Earnings

Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) - Equities research analysts at Leerink Partnrs dropped their FY2028 earnings estimates for shares of Tandem Diabetes Care in a report issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now forecasts that the medical device company will post earnings of $0.00 per share for the year, down from their previous estimate of $0.01. The consensus estimate for Tandem Diabetes Care's current full-year earnings is ($1.73) per share.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its earnings results on Wednesday, November 6th. The medical device company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.08. The company had revenue of $243.97 million during the quarter, compared to the consensus estimate of $224.14 million. Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. Tandem Diabetes Care's quarterly revenue was up 31.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.38) earnings per share.

TNDM has been the subject of several other research reports. Canaccord Genuity Group assumed coverage on shares of Tandem Diabetes Care in a research report on Thursday, August 8th. They set a "buy" rating and a $57.00 price target for the company. The Goldman Sachs Group initiated coverage on shares of Tandem Diabetes Care in a research note on Friday, October 4th. They issued a "neutral" rating and a $46.00 price target on the stock. Piper Sandler reiterated an "overweight" rating and set a $55.00 price objective (up from $50.00) on shares of Tandem Diabetes Care in a research report on Friday, August 2nd. Canaccord Genuity Group lowered their target price on Tandem Diabetes Care from $57.00 to $56.00 and set a "buy" rating on the stock in a research report on Thursday, November 7th. Finally, Morgan Stanley reiterated an "equal weight" rating and set a $45.00 price target on shares of Tandem Diabetes Care in a research report on Monday, September 23rd. Five equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, Tandem Diabetes Care presently has a consensus rating of "Moderate Buy" and an average price target of $54.25.

Tandem Diabetes Care Stock Performance

TNDM traded down $0.38 during trading on Tuesday, reaching $30.04. 1,311,516 shares of the company were exchanged, compared to its average volume of 1,603,749. Tandem Diabetes Care has a 52 week low of $18.45 and a 52 week high of $53.69. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. The firm has a 50 day moving average of $35.91 and a 200 day moving average of $41.14. The stock has a market cap of $1.97 billion, a P/E ratio of -15.76 and a beta of 1.36.

Institutional Trading of Tandem Diabetes Care

A number of institutional investors have recently added to or reduced their stakes in the business. Brooklyn Investment Group bought a new position in shares of Tandem Diabetes Care during the 3rd quarter valued at $28,000. Assetmark Inc. acquired a new stake in shares of Tandem Diabetes Care in the third quarter worth about $29,000. ORG Wealth Partners LLC bought a new stake in shares of Tandem Diabetes Care during the 3rd quarter worth about $30,000. ORG Partners LLC acquired a new position in shares of Tandem Diabetes Care during the 2nd quarter valued at about $31,000. Finally, Waldron Private Wealth LLC acquired a new position in shares of Tandem Diabetes Care during the 3rd quarter valued at about $50,000.

Insider Activity at Tandem Diabetes Care

In related news, Director Kim D. Blickenstaff sold 10,000 shares of the business's stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $30.00, for a total value of $300,000.00. Following the completion of the sale, the director now owns 195,190 shares of the company's stock, valued at approximately $5,855,700. The trade was a 4.87 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 2.20% of the stock is currently owned by insiders.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.